A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis.
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2013
At a glance
- Drugs AMG 557 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- 13 Jul 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 06 Mar 2012 Additional lead trial investigator identified as reported by Oregon Health and Science University Institutional Review Board.
- 06 Mar 2012 New source identified and integrated (IRB00007784; Oregon Health and Science University Institutional Review Board).